Summary of Significant Accounting Policies (Tables)

9 Months Ended

12 Months Ended

Mar. 31, 2021

Jun. 30, 2020

Accounting Policies [Abstract]

Disaggregation of revenues

	Benchtop Laboratory Equipment		Bioprocessing Systems		Consolidated
Three Months Ended March 31, 2021:
Revenues	$	2,365,700	$	142,900	$	2,508,600
Foreign Sales		942,200		102,600		1,044,800

	Benchtop Laboratory Equipment		Bioprocessing Systems		Consolidated
Three Months Ended March 31, 2020:
Revenues	$	1,800,700	$	335,500	$	2,136,200
Foreign Sales		743,000		335,000		1,078,000

	Benchtop Laboratory Equipment		Bioprocessing Systems		Consolidated
Nine Months Ended March 31, 2021:
Revenues	$	6,803,300	$	441,800	$	7,245,100
Foreign Sales		2,724,800		395,000		3,119,800

	Benchtop Laboratory Equipment		Bioprocessing Systems		Consolidated
Nine Months Ended March 31, 2020:
Revenues	$	5,320,300	$	914,200	$	6,234,500
Foreign Sales		1,996,400		913,700		2,910,100

	Benchtop Laboratory Equipment		Bioprocessing Systems		Corporate and Other		Consolidated
June 30, 2020:
Revenues	$	6,783,600	$	1,000,800	$	—	$	7,784,400
Foreign Sales		2,589,800		1,000,400		586,500		4,176,700

	Benchtop Laboratory Equipment		Bioprocessing Systems		Corporate and Other		Consolidated
June 30, 2019:
Revenues	$	7,078,800	$	1,306,100	$	—		8,384,900
Foreign Sales		2,680,300		1,301,200		1,102,300		5,083,800